For Biotech
MyImmune acts as your strategic navigation system, decoding the adaptive immune repertoire to increase your Probability of Technical and Regulatory Success (PTRS) and optimize capital efficiency.
"Human-Validated" Target Discovery
De-risk early-stage assets by bypassing flawed animal models and risky Generative AI "hallucinations." We identify highly specific antigens and binders already proven safe by the human immune system.
Trial Insurance & Phase II Rescue
Avoid unstratified "all-comer" trials. We retrospectively rescue struggling Phase II assets by identifying hidden responder sub-populations from baseline blood draws. Prospectively enrich Phase III trials to run smaller, cheaper "sniper" cohorts that extend your cash runway.
Asset-Specific Solutions
ADCs (Optimization)
Validate in vivo functional epitopes. Predict cross-reactive immunity to prevent off-target toxicities that derail programs.
Checkpoint Inhibitors (Rescue)
Analyze banked samples from equivocal Phase II trials to pinpoint true responders and resurrect stalled assets.
Cell Therapies (Safety)
Profile baseline repertoires to predict severe Cytokine Release Syndrome (CRS) and neurotoxicity (ICANS) pre-infusion.
De-Risk Your Pipeline & Maximize PTRS
Don't let biological heterogeneity derail your assets. Contact us or schedule an appointment to establish a partnership. We will rescue stalled trials, validate targets, and maximize your PTRS.